SUN PHARMACEUTICAL IND L vs TARSONS PRODUCTS LIMITED

A side-by-side comparison of SUN PHARMACEUTICAL IND L (SUNPHARMA) and TARSONS PRODUCTS LIMITED (TARSONS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads SUNPHARMA vs TARSONS on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

40.40
P/E ratio
106.86
5.57
P/B ratio
2.23
0.83%
Dividend yield
0.69%
₹47.84
EPS
₹2.69

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.00%
Return on equity
2.38%
21.00%
Return on capital
5.00%
30.00%
EBITDA margin
28.00%
19.69%
Net margin
3.31%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.03%
Revenue CAGR (3Y)
14.30%
10.57%
Profit CAGR (3Y)
-44.23%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹4.64L Cr
Market cap
₹1,552 Cr
₹58,462 Cr
Revenue
₹423 Cr
₹11,509 Cr
Net profit
₹14 Cr
0.06
Debt / equity
0.62
SUN PHARMACEUTICAL IND L
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
TARSONS PRODUCTS LIMITED
  • ["Stock is trading at 2.54 times its book value", "Though the company is reporting repeated profits, it is not paying out dividend", "Company has a low return on equity of 4.68% over last 3 years.", "Company might be capitalizing the interest cost"]
SUN PHARMACEUTICAL IND L full analysis TARSONS PRODUCTS LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.